Oxycodonhydrochlorid Stada (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Oxycodonhydrochlorid Stada, is an opioid analgesic presented as a strength/form for oral use. It treats moderate to severe pain in adult patients when other analgesics are insufficient. GNH USA supplies Oxycodonhydrochlorid Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxycodonhydrochlorid Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxycodone Hydrochloride is used in the management of pain across several clinical contexts.

- Acute postoperative pain: provides rapid relief of moderate to severe pain following surgery. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Chronic non‑cancer pain: used when long‑term opioid therapy is deemed appropriate for conditions such as severe osteoarthritis. - Trauma‑related pain: alleviates severe pain resulting from injuries such as fractures. - Palliative care: contributes to comfort in end‑of‑life care by managing severe pain.

Adverse reactions to oxy‑hydroxycodone may vary in frequency and severity.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea: mild to moderate queasiness. - Drowsiness: increased sedation. - Dizziness: light‑headed sensation. - Dry mouth: decreased salivation. - Pruritus: mild skin itching.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Opioid use disorder: risk of dependence and addiction. - Adrenal insufficiency: impaired cortisol production. - Anaphylaxis: acute allergic reaction. - Seizures: rare convulsive episodes.

When prescribing oxycodone hydrochloride, clinicians should consider several safety measures.

- Assess pain severity and opioid history: ensure appropriate indication before initiating therapy. - Monitor for respiratory depression: especially during dose initiation and after dose adjustments. - Evaluate renal and hepatic function: adjust dosing in impairment. - Avoid concurrent CNS depressants: limit additive sedation risk. - Educate patients on constipation management: recommend diet, fluids, and laxatives. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Oxycodone hydrochloride can interact with a range of concomitant medications.

Major Interactions (Avoid): - Benzodiazepines: combined use markedly increases risk of respiratory depression. - Central nervous system depressants: additive sedation and respiratory effects. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increase oxycodone plasma levels. - CYP3A4 inducers (e.g., rifampicin): reduce oxyhydroxy   - Anticholinergic agents: may worsen constipation. - Serotonergic drugs: potential for serotonin syndrome. - Alcohol: enhances sedative effects.